Presentation

Analysis of Pre-Exposure Prophylaxis Utilization in a Medicaid Population

Warren Smith, PharmD
Mckenzie Taylor, PharmD Headshot
Mckenzie Taylor, PharmD Managed Care Pharmacy Resident, Clinical Pharmacy Services
Thomas Pomfret, PharmD, MPH, BCPS Headshot
Thomas Pomfret, PharmD, MPH, BCPS Clinical Consultant Pharmacist Team Lead and Residency Program Director, Clinical Pharmacy Services
Stephanie Tran, PharmD, BCPS
Pavel Lavitas, PharmD, BCPS Headshot
Pavel Lavitas, PharmD, BCPS Clinical Team Lead, Clinical Pharmacy Services
Caroline J. Alper, MD
Mark Tesell, PharmD, BCPS Headshot
Mark Tesell, PharmD, BCPS
Karen Clements, ScD Headshot
Karen Clements, ScD Senior Project Director, Research and Evaluation
Kimberly Lenz, PharmD, MBA, FAMCP Headshot
Kimberly Lenz, PharmD, MBA, FAMCP Senior Pharmacy Director, MassHealth/Office of Clinical Affairs

Approximately two million new cases of human immunodeficiency virus (HIV) infection occur every year. Adhering to a pre-exposure prophylaxis therapy(PrEP) allows patients to reduce their risk of transmission by about 90%, but adherence to the therapy can vary a great deal. This presentation evaluates the utilization of two PrEP therapies, emtricitabine/tenofovir disoproxil fumarate (Truvada®) and emtricitabine/tenofovir alafenamide (Descovy®), among a MassHealth population.

UMASS_Poster_CPS_AnalysisPreExPUMP_2021_v3.pdf